This FDA-approved generic version of Rectiv® is aimed at treating chronic anal fissure pain and taps into a growing market exceeding $23 million. The launch strengthens Acrux’s strategy to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results